Asahi shares mark weekly slide after cyberattack halts production
Beta Bionics (EXCHANGE:BBNX) Chief Commercial Officer Mark Hopman sold 18,229 shares of common stock on September 4 and 5, 2025, for approximately $370,836. The sales occurred at weighted average prices ranging from $19.9736 to $20.5641 per share. The stock, which has surged 22.77% in the past week, currently trades at $23.13, near its 52-week high of $24.50. According to InvestingPro analysis, the stock appears overvalued at current levels, with technical indicators suggesting overbought conditions.
The sales were executed under a Rule 10b5-1 Plan adopted on May 13, 2025. On the same dates, Hopman exercised options to acquire a total of 16,160 shares of Beta Bionics common stock at a price of $5.10, for a total value of $82,416. The company, with a market capitalization of $878.1 million, maintains a strong balance sheet with more cash than debt, though analysts don’t expect profitability this year. Get access to 10+ additional key insights about Beta Bionics with InvestingPro.
In other recent news, Beta Bionics reported its second-quarter earnings for 2025, revealing significant financial improvements. The company posted an earnings per share (EPS) of -$0.39, which surpassed the forecast of -$0.42. Additionally, Beta Bionics experienced a 54% year-over-year increase in net sales, reaching $23.2 million. These results were bolstered by better-than-expected revenue and gross margins, driven by strong new patient starts and exceptional performance in the pharmacy benefit provider channel. Following these positive earnings and revenue outcomes, Truist Securities raised its price target for Beta Bionics from $18.00 to $21.00, while maintaining a Buy rating. This adjustment reflects confidence in the company’s continued growth. These developments highlight the company’s robust performance in the recent quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.